RJF vs ZYME · rev $15.91B vs rev $106.0M
RJF (RJF) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
RJF (RJF) common stock.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported RJF revenue for 2025-09-30 was $15.91B. Net income was $2.13B. Revenue was up 6.6% from 2024-09-30 to 2025-09-30. RJF currently screens at market cap $0.
Latest reported ZYME revenue for 2025-12-31 was $106.0M. Net income was -$81.1M. Revenue was up 38.9% from 2024-12-31 to 2025-12-31. ZYME currently screens at market cap $1.68B.
RJF currently screens at market cap $0. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the RJF and ZYME stock pages for the full models.
Not investment advice.